External broker reports(aggregated public sources), Axis Direct

Axis Direct

External broker reports(aggregated public sources)

Axis Direct is the flagship brand under Axis Securities Limited, a subsidiary of Axis Bank in India. 

Content available is external broker reports authored by a third party outside the Smartkarma network and has been aggregated by an online aggregator through publicly available sources and is displayed by Smartkarma in this format for user's convenience and general informational purposes only. Content does not constitute investment or financial advice and Smartkarma makes no representation or warranty regarding its accuracy or contents. Original third party author retains all copyright and other proprietary rights in the content. Access or use of third party links not controlled by Smartkarma are at the user's own risk.

Equity Bottom-Up

<ul><li>Biocon Limited is one of India's premier biopharmaceutical companies, offering high-quality biosimilars, complex small molecule APIs, and generic formulations globally.</li><li>Equipped with state-of-the-art biomanufacturing facilities and advanced fermentation platforms, it consistently delivers affordable, life-saving biologic therapies across oncology, diabetes, and immunology.</li><li>Beyond its core biopharma operations, its integrated ecosystem extends capabilities through Syngene for contract research and development services.</li></ul>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Biocon Limited is one of India's premier biopharmaceutical companies, offering high-quality biosimilars, complex small molecule APIs, and generic formulations globally.Equipped with state-of-the-art biomanufacturing facilities and advanced fermentation platforms, it consistently delivers affordable, life-saving biologic therapies across oncology, diabetes, and immunology.Beyond its core biopharma operations, its integrated ecosystem extends capabilities through Syngene for contract research and development services.Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Pick of the Week: Biocon - 19th September, 2026

Thematic (Sector/Industry)

<ul><li>Pharmaceuticals: We expect pharmaceutical companies under our coverage to deliver a subdued yet positive performance in Q2FY27, with aggregate revenue rising 7.0% YoY and 3.6% QoQ to Rs 40,903 Cr.</li><li>However, EBITDA is estimated to decline 10% YoY but rise 6.3% QoQ to Rs 8,308 Cr, while adjusted PAT is likely to decline 19.6% YoY but moderately rise by 4.2% sequentially to Rs 4,331 Cr.</li><li>According to IQVIA data, chronic care segments such as cardiovascular and antidiabetic treatments are sustaining their outperformance against the broader Indian Pharmaceutical Market. </li></ul>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Pharmaceuticals: We expect pharmaceutical companies under our coverage to deliver a subdued yet positive performance in Q2FY27, with aggregate revenue rising 7.0% YoY and 3.6% QoQ to Rs 40,903 Cr.However, EBITDA is estimated to decline 10% YoY but rise 6.3% QoQ to Rs 8,308 Cr, while adjusted PAT is likely to decline 19.6% YoY but moderately rise by 4.2% sequentially to Rs 4,331 Cr.According to IQVIA data, chronic care segments such as cardiovascular and antidiabetic treatments are sustaining their outperformance against the broader Indian Pharmaceutical Market. Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Pharma and Healthcare - Q2FY27E: Result Preview

Smartkarma AI Primers, Smartkarma

αSK Primers

Smartkarma AI Primers

Smartkarma

Smartkarma unites the fragmented investment industry, connecting institutional investors, independent research providers, and corporates within a single network.

Research Reinvented

<ul>
 <li>Biocon is strategically positioned to capitalize on the burgeoning global biosimilars market, leveraging its integrated business model and recent acquisition of Viatris' biosimilar assets to drive future growth.</li>
 <li>The company faces significant near-term headwinds from high financial leverage and declining profitability, as evidenced by negative net income and free cash flow growth over the past several years.</li>
 <li>Valuation appears stretched, with a Price-to-Earnings (PE) ratio significantly higher than its peer group, suggesting the market has priced in a successful execution of its biosimilar pipeline and deleveraging strategy.</li>
</ul>This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.


  Biocon is strategically positioned to capitalize on the burgeoning global biosimilars market, leveraging its integrated business model and recent acquisition of Viatris' biosimilar assets to drive future growth.
  The company faces significant near-term headwinds from high financial leverage and declining profitability, as evidenced by negative net income and free cash flow growth over the past several years.
  Valuation appears stretched, with a Price-to-Earnings (PE) ratio significantly higher than its peer group, suggesting the market has priced in a successful execution of its biosimilar pipeline and deleveraging strategy.
This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

India Equity Analyst - Fundamental & Thematic, Beat the Street

Sudarshan Bhandari

India Equity Analyst - Fundamental & Thematic

Beat the Street

Beat The Street was founded by Nimish Maheshwari and Sudarshan Bhandari, both of whom are Chartered Accountants by Profession, known for their expert analysis in the fields of Business, Sectoral analysis, and Corporate governance.

With a strong social media presence of 45,000+ Subscribers across various platforms, they are considered trusted voices in the industry. Their insights and analysis have been featured in some of India’s most prominent publications, including the Economic Times, Dalal Street Investment Journal, The Morning Context, and The Ken.

Their analysis on Bankrupt & Insolvent companies has been instrumental in saving investors from significant losses. They have a keen eye for identifying red flags and has identified exclusive redflags earlier in Vedanta, Nykaa, Dhani Services, Adani and many more.

Read Business Not Stock Prices

<ul>
<li>Biocon, a global biopharmaceutical company, saw Mylan exit its entire 5.64% stake through a INR 3,680 crore block deal, removing a major ownership overhang.</li>
<li>The transaction is earnings-neutral but improves liquidity and price discovery, allowing investors to refocus on FY27 biosimilar launches, generics utilisation, deleveraging and Syngene recovery.</li>
<li>With integration largely done and deleveraging underway, FY27 is the year Biocon has to prove the biosimilars-insulin-GLP-1 bet actually pays for itself.</li>
</ul>


Biocon, a global biopharmaceutical company, saw Mylan exit its entire 5.64% stake through a INR 3,680 crore block deal, removing a major ownership overhang.
The transaction is earnings-neutral but improves liquidity and price discovery, allowing investors to refocus on FY27 biosimilar launches, generics utilisation, deleveraging and Syngene recovery.
With integration largely done and deleveraging underway, FY27 is the year Biocon has to prove the biosimilars-insulin-GLP-1 bet actually pays for itself.


Market & Forensics Analyst, Beat the Street

Nimish Maheshwari

Market & Forensics Analyst

<ul>
<li>On 20th March 2026, the critical patent for Semaglutide expires in India, decisively ending the innovator's legal monopoly and enabling highly affordable generic versions. </li>
<li>This triggers a massive 70% retail price drop in India, exponentially expanding affordable access to millions suffering from prevalent obesity and diabetes.</li>
<li>Vertically integrated formulators like Sun Pharma and specialized API manufacturers like Divis Laboratories capture maximum alpha through scaled volumes and zero customer acquisition costs.</li>
</ul>


On 20th March 2026, the critical patent for Semaglutide expires in India, decisively ending the innovator's legal monopoly and enabling highly affordable generic versions. 
This triggers a massive 70% retail price drop in India, exponentially expanding affordable access to millions suffering from prevalent obesity and diabetes.
Vertically integrated formulators like Sun Pharma and specialized API manufacturers like Divis Laboratories capture maximum alpha through scaled volumes and zero customer acquisition costs.


The GLP-1 Super-Cycle: Deconstructing India’s 2026 Patent Cliff and Alpha Generators

India

Biocon Ltd., is an integrated biotechnology enterprise with a presence in biopharmaceuticals, enzymes, custom research and clinical research. The Company's pharmaceutical products include statins, immunosuppressants and anti-diabetic drugs. Biocon also manufactures specialty enzymes and new enzyme applications besides providing clinical and custom research services.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Biocon Ltd (BIOS IN)

Pick of the Week: Biocon - 19th September, 2026

Biocon Limited is one of India's premier biopharmaceutical companies, offering high-quality biosimilars, complex small molecule APIs, and generic...

Axis Direct

Pharma and Healthcare - Q2FY27E: Result Preview

We expect pharmaceutical companies under our coverage to deliver a subdued yet positive performance in Q2FY27, with aggregate revenue rising 7.0%...

Axis Direct

Primer: Biocon Ltd (BIOS IN) - Aug 2026

Biocon is strategically positioned to capitalize on the burgeoning global biosimilars market, leveraging its integrated business model and...

αSK Primers

Biocon: Can It Be Next Laurus Labs?

Biocon sees Mylan exit its stake, improving liquidity and refocusing on upcoming launches and deleveraging to prove biosimilar bet pays off.

Sudarshan Bhandari

The GLP-1 Super-Cycle: Deconstructing India’s 2026 Patent Cliff and Alpha Generators

Semaglutide patent expiration in India leads to 70% price drop, increasing access to affordable generic versions for obesity and diabetes treatment.

Nimish Maheshwari

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)

Pick of the Week: Biocon - 19th September, 2026

Biocon Limited is one of India's premier biopharmaceutical companies, offering high-quality biosimilars, complex small molecule APIs, and generic...

Axis Direct

Pharma and Healthcare - Q2FY27E: Result Preview

We expect pharmaceutical companies under our coverage to deliver a subdued yet positive performance in Q2FY27, with aggregate revenue rising 7.0%...

Axis Direct

Primer: Biocon Ltd (BIOS IN) - Aug 2026

Biocon is strategically positioned to capitalize on the burgeoning global biosimilars market, leveraging its integrated business model and...

αSK Primers

Biocon: Can It Be Next Laurus Labs?

​Biocon sees Mylan exit its stake, improving liquidity and refocusing on upcoming launches and deleveraging to prove biosimilar bet pays off.

Sudarshan Bhandari

The GLP-1 Super-Cycle: Deconstructing India’s 2026 Patent Cliff and Alpha Generators

​Semaglutide patent expiration in India leads to 70% price drop, increasing access to affordable generic versions for obesity and diabetes treatment.

Nimish Maheshwari

Biocon sees Mylan exit its stake, improving liquidity and refocusing on upcoming launches and deleveraging to prove biosimilar bet pays off.

Semaglutide patent expiration in India leads to 70% price drop, increasing access to affordable generic versions for obesity and diabetes treatment.